Prediction of homologous recombination deficiency from Oncomine Comprehensive Assay Plus correlating with SOPHiA DDM HRD Solution.
<h4>Objective</h4>Poly(ADP-ribose) polymerase (PARP) inhibitors are used for targeted therapy for ovarian cancer with homologous recombination deficiency (HRD). In this study, we aimed to develop a homologous recombination deficiency prediction model to predict the genomic integrity (GI)...
Main Authors: | Jun Kang, Kiyong Na, Haeyoun Kang, Uiju Cho, Sun Young Kwon, Sohyun Hwang, Ahwon Lee |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2024-01-01
|
Series: | PLoS ONE |
Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0298128&type=printable |
Similar Items
-
Oncomine™ Comprehensive Assay v3 vs. Oncomine™ Comprehensive Assay Plus
by: Lau K. Vestergaard, et al.
Published: (2021-10-01) -
Homologous Recombination Deficiency (HRD) in Cutaneous Oncology
by: Favour A. Akinjiyan, et al.
Published: (2023-06-01) -
Concordance between Three Homologous Recombination Deficiency (HRD) Assays in Patients with High-Grade Epithelial Ovarian Cancer
by: Elena Fountzilas, et al.
Published: (2023-11-01) -
Accurate tumor purity determination is critical for the analysis of homologous recombination deficiency (HRD)
by: Michael Menzel, et al.
Published: (2023-09-01) -
Analytical Validation and Clinical Utilization of the Oncomine Comprehensive Assay Plus Panel for Comprehensive Genomic Profiling in Solid Tumors
by: Catherine I. Dumur, et al.
Published: (2023-06-01)